Rifaximin Dosage and Efficacy for Diarrhea
Dosing by Indication
- The American Gastroenterological Association (AGA) endorses a regimen of 550 mg three times daily for 14 days for Irritable Bowel Syndrome with Diarrhea (IBS-D), based on moderate-quality evidence from phase 3 trials 1, 2
- Patients with IBS-D who respond initially but experience symptom recurrence can be retreated up to 2 times with the same dosage regimen of 550 mg three times daily for 14 days 1, 2, 3
Important Clinical Considerations
- For non-invasive pathogens, rifaximin is highly effective, but for invasive pathogens, such as Shigella, Campylobacter, and Salmonella, azithromycin is preferred over rifaximin 5
- The AGA recommends against exceeding 2 retreatment courses for IBS-D, as safety data beyond this are limited 1, 2
Safety Profile
- Rifaximin has a low risk of Clostridium difficile infection compared to systemically absorbed antibiotics 6